Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
07:30am, Monday, 04'th Jan 2021
WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pat
Aquestive Therapeutics: Back From The Brink, ~57% Upside Potential In New Asset Structuring
03:06pm, Wednesday, 16'th Dec 2020
Aquestive Therapeutics are back from the brink, with key advancements in Libervant resubmission and longevity in shareholder value creation. The company entered into a royalty agreement for KYNMOBI, w
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
09:15am, Wednesday, 25'th Nov 2020
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pat
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
07:00am, Monday, 23'rd Nov 2020
Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 mi
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
04:01pm, Wednesday, 18'th Nov 2020
WARREN, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pat
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript
05:12am, Sunday, 08'th Nov 2020
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
04:30pm, Wednesday, 04'th Nov 2020
WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pati
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
07:00am, Tuesday, 03'rd Nov 2020
WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pat
Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher
03:06pm, Tuesday, 18'th Aug 2020
Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Aquestive Therapeutics (AQST) Investor Presentation - Slideshow
06:07pm, Thursday, 13'th Aug 2020
The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this event..
* Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 * First planned PK clinical trial expected to begin during the third quarter of 2020WARREN, N.J., Aug. 10, 2020 (GLOBE
Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush - Markets
01:35pm, Sunday, 09'th Aug 2020
In a report issued on August 7, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST –
Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call Transcript
10:31pm, Wednesday, 05'th Aug 2020
Good morning and welcome to today's call to review Aquestive Therapeutics' results for the second-quarter 2020 and business highlights. On today's call, I am joined by Keith Kendall, president and ch
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
11:35pm, Tuesday, 04'th Aug 2020
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
* Generated 59% year-over-year revenue growth for Sympazan®(clobazam) * FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokineti
